Using Virtual Reality to Reduce Procedural Pain in Children With Cancer
17. April 2020 aktualisiert von: Jennifer Stinson, The Hospital for Sick Children
Using Virtual Reality to Reduce Procedural Pain in Children With Cancer: A Pilot Randomized Controlled Trial
This study will assess the impact of virtual reality (VR) in decreasing procedural pain related to subcutaneous port (SCP) access in children with cancer.
The study is a pilot-randomized controlled trial (RCT) using a cross-over design that will provide us with detailed information on the feasibility of implementing our trial protocol in a future multi-center RCT as well as preliminary estimate of VR treatment effect on children with cancer undergoing SCP access, including child and parent factors potentially associated with VR distraction treatment efficacy.
Studienübersicht
Detaillierte Beschreibung
The study is a repeated-measures cross-over pilot RCT to examine the feasibility of the trial protocol for a study into the effectiveness of immersive VR in minimizing procedural pain and distress in children with cancer.
The research objectives are to: (1) pilot implementing immersive virtual reality (VR) for effectiveness testing in a future RCT (measured as implementation outcomes); (2) determine treatment effect sizes (measured as preliminary effectiveness outcomes), between VR, programmed to distract children during an SCP needle insertion, and an active control intervention (i.e., watching a video with headphones); and (3) assess impact of child and parent factors potentially associated with VR treatment effectiveness.
Both the intervention and control groups will receive standard medical care (e.g., topical anesthetics).
A convenience sample of 40 children and adolescents with cancer (20 participants per treatment arm; 10 boys and 10 girls per treatment arm) will be recruited.
In addition, each child will act as their own control.
A washout period of 1 month will be used to control for any carry-over effect between conditions.
In addition to usual care, children in the experimental condition will wear the VR headset plus headphones.
In the control condition, children will watch a video (i.e., an age-appropriate video selected by an oncology-affiliated child life specialist) on an iPad, while wearing the same headphones as in the experimental condition.
Implementation outcomes include accrual and retention rates, acceptability and technical difficulties.
Effectiveness outcomes include child pain, distress, and fear, as well as parent distress.
Studientyp
Interventionell
Einschreibung (Tatsächlich)
40
Phase
- Unzutreffend
Kontakte und Standorte
Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.
Studienorte
-
-
Ontario
-
Toronto, Ontario, Kanada, M5G 1X8
- Hospital for Sick Children
-
-
Teilnahmekriterien
Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.
Zulassungskriterien
Studienberechtigtes Alter
8 Jahre bis 18 Jahre (Kind, Erwachsene)
Akzeptiert gesunde Freiwillige
Nein
Studienberechtigte Geschlechter
Alle
Beschreibung
Inclusion Criteria:
- Child and parent able to speak and understand English
- actively undergoing cancer treatment
- being less than 1 year from initial diagnosis
- requiring at least 2 SCP needle insertions for cancer treatment over the following 8 weeks
Exclusion Criteria:
- visual, auditory or cognitive impairments precluding interaction with the intervention or control equipment
- patients with major co-morbid medical or psychiatric conditions (including needle-phobia_ as per their healthcare provider or parent
- end of life patients
- patients with a MRSA infection or symptoms of respiratory or gastrointestinal infection as per any member of their healthcare team which could contaminate the intervention or control equipment
- participation in usability study
Studienplan
Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Crossover-Aufgabe
- Maskierung: Single
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Intervention Group
In addition to usual care, the intervention group will receive the Samsung GearVR with head mounted display (HMD), controller, and headphones.
They will situated in front of the nurse and beside/on the lap of the parent, or they may be lying supine.
The VR intervention will use auditory and visual stimuli (simulating the peaceful underwater environment) to distract the child before, during, and after the SCP needle insertion.
Children will be allowed to 'try-out' the VR system before the SCP access to familiarize themselves with the equipment.
The entire study will be videotaped.
|
VR with head mounted display (HMD) and headphones.
Treatment
|
|
Aktiver Komparator: Control Group
In addition to usual care, participants in the control group will be seated with their parent and in front of the nurse, according to preference.
Children will watch an age appropriate video selected by an oncology-affiliated child life specialist on an iPad, while wearing the same headphones used in the experimental condition.
The RA will hold the iPad and positioned within a meter of the child so that the child can still see the iPad without the RA interfering in the clinical procedure.
The entire study will be videotaped.
|
iPad with headphones. Control
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Accural Rates/Retention Rates
Zeitfenster: 6 months
|
Using a recruitment log to measure eligible children per recruitment day, reasons for ineligibility, reasons for non-participation and reasons for study attrition.
|
6 months
|
|
Acceptability
Zeitfenster: 6 months
|
Measured using the VR Distraction Satisfaction Questionnaire completed by children and nurses and will collect data on acceptability, perceived utility of pain reducing procedures, and recommendations for changes related to the needle insertion experience.
|
6 months
|
|
Outcome measure feasibility
Zeitfenster: 6 months
|
Will be measured as the percentage of completed outcome measures at baseline and study completion and will be recorded on the VR Distraction Activity Log
|
6 months
|
|
Technical Difficulties/Practical Difficulties
Zeitfenster: 6 months
|
Record data related to technical/practical difficulties associated with the VR intervention, RA observed difficulties in implementing the trial protocol in the clinic and time to complete SCP access.
|
6 months
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Pain Intensity
Zeitfenster: 6 months
|
For both pre and post study procedures, children will self report their pain and parents, nurses and the RA will report children's pain using an 11 point NRS scale (0 being no pain at all and 10 being the most pain you can imagine this child or you having)
|
6 months
|
|
Child Distress
Zeitfenster: 6 months
|
For both pre and post study procedures, distress during the SCP study will be measured using the observer-rated Behavioural Approach-Avoidance Scale (BAADS). 2 research team members will code video-recordings from all SCP needle insertion using the BAADS.
|
6 months
|
|
Child Fear
Zeitfenster: 6 months
|
Children will report fear both prior to and following the procedure using the CFS which is a visual scale with established psychometrics in children as young as 5.
|
6 months
|
|
Child Pain Catastrophizing
Zeitfenster: 6 months
|
Children will report baseline tendencies to catastrophize about pain using the PCS-C.
|
6 months
|
|
Parent Pain Catastrophizing
Zeitfenster: 6 months
|
Parents will report baseline tendencies to catastrophize about their child's pain using the PCS-P which is a self-reporting measure of pain.
|
6 months
|
|
Parent Distress
Zeitfenster: 6 months
|
Parents will report on their own level of distress following the child's procedure using the Parent Distress Questionnaire.
|
6 months
|
Mitarbeiter und Ermittler
Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.
Sponsor
Ermittler
- Hauptermittler: Jennifer Stinson, RN, NP, PhD, The Hospital for Sick Children
Studienaufzeichnungsdaten
Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.
Haupttermine studieren
Studienbeginn (Tatsächlich)
1. August 2017
Primärer Abschluss (Tatsächlich)
31. Dezember 2019
Studienabschluss (Tatsächlich)
31. Dezember 2019
Studienanmeldedaten
Zuerst eingereicht
7. Oktober 2016
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
7. Oktober 2016
Zuerst gepostet (Schätzen)
11. Oktober 2016
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
20. April 2020
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
17. April 2020
Zuletzt verifiziert
1. April 2020
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- 1000053757
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Ja
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Nein
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Nein
Produkt, das in den USA hergestellt und aus den USA exportiert wird
Nein
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .